Benzinga | Jul 15, 2020 07:16AM EDT

SVB Leerink Maintains Outperform on Blueprint Medicines, Raises Price Target to $106

SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $105 to $106.